480 Biomedical, Inc. Receives $1.2M from Broadview
June 18, 2015
June 18, 2015, Watertown, MA — 480 Biomedical, Inc., a clinical stage company developing novel bioresorbable scaffold products for the vasculature, announced today $1.2 million in funding from Broadview Ventures. The financing is a second close on a previously announced $10.5 million in Series C funding round from existing investors.
The Broadview funds will support the development of a bioresorbable scaffold to treat children with pulmonary artery stenosis (PAS), a narrowing in the branches of the pulmonary artery that reduces blood flow to the lungs and can lead to heart failure.